Ensitrelvir, an antiviral being developed to prevent COVID-19, reduced the risk of developing the infection by 67% in uninfected people after exposure to SARS-CoV-2 compared with placebo at day 10, according to results presented at CROI 2025, held in San Francisco (abstract 200).
The 67% reduction is “super exciting,” said Diane Havlir, MD, the CROI chair, and the chief of the HIV, Infectious Diseases and Global Medicine Division at Zuckerberg San Francisco